Journal of Neuro-Oncology

, Volume 14, Issue 1, pp 63–72

Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma

Final report of a prospective phase I–II dose response study
  • D. S. Fulton
  • R. C. Urtasun
  • I. Scott-Brown
  • E. S. Johnson
  • B. Mielke
  • B. Curry
  • D. Huyser-Wierenga
  • J. Hanson
  • M. Feldstein
Clinical study

DOI: 10.1007/BF00170946

Cite this article as:
Fulton, D.S., Urtasun, R.C., Scott-Brown, I. et al. J Neuro-Oncol (1992) 14: 63. doi:10.1007/BF00170946

Abstract

We attempted to show a dose effect relationship for radiation therapy by treating patients harbouring malignant glioma with increasing doses of radiation in a step-wise fashion. We postulated that no increase in delayed toxicity would be seen because we used hyperfractionation technique. Between January 1981 and December 1988 we treated 280 patients three times daily at 4 hour intervals. 100 patients received a total dose of 6141 cGy, 73 patients received 7120 cGy, and 107 patients received 8000 cGy. CCNU was given at the time of tumor progression following radiotherapy. Median time to tumor progression was 28 weeks for patients who received 6141 cGy, 27 weeks for patients who received 7120 cGy and 36 weeks for patients who received 8000 cGy. Median survival was 46 weeks for patients who received 6141 cGy, 38 weeks for patients who received 7120 cGy and 45 weeks for patients who received 8000 cGy. There was no statistically significant difference in either time to tumor progression or survival among the three treatment arms and no dose response effect was seen. There was no increase in delayed radiation toxicity when the total radiation dose was increased up to 8000 cGy.

Key words

hyperfractionation malignant glioma radiation therapy 

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • D. S. Fulton
    • 1
  • R. C. Urtasun
    • 1
  • I. Scott-Brown
    • 2
  • E. S. Johnson
    • 3
  • B. Mielke
    • 3
  • B. Curry
    • 4
  • D. Huyser-Wierenga
    • 1
  • J. Hanson
    • 5
  • M. Feldstein
    • 6
  1. 1.Department of Radiation OncologyCross Cancer Institute and University of AlbertaCanada
  2. 2.Department of Radiation Oncology, Tom Baker Cancer CenterUniversity of CalgaryCalgaryCanada
  3. 3.Department of PathologyUniversity of AlbertaEdmontonCanada
  4. 4.Department of PathologyUniversity of CalgaryCalgaryCanada
  5. 5.Department of Epidemiology, Cross Cancer InstituteUniversity of AlbertaEdmontonCanada
  6. 6.Frontier Science and TechnologyResearch Foundation Inc.Brookline
  7. 7.Cross Cancer InstituteEdmontonCanada

Personalised recommendations